Ieq Capital LLC Purchases Shares of 440 argenx SE (NASDAQ:ARGX)

Ieq Capital LLC acquired a new position in argenx SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 440 shares of the company’s stock, valued at approximately $271,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Global Retirement Partners LLC boosted its position in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of argenx during the fourth quarter valued at about $66,000. Nkcfo LLC acquired a new stake in argenx in the fourth quarter worth about $68,000. Advisors Preferred LLC bought a new position in argenx in the 4th quarter valued at about $73,000. Finally, Financial Perspectives Inc increased its stake in argenx by 39.4% during the 4th quarter. Financial Perspectives Inc now owns 145 shares of the company’s stock valued at $89,000 after buying an additional 41 shares during the period. 60.32% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Oppenheimer lifted their price target on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday. Guggenheim upped their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Stock Down 0.0 %

ARGX opened at $624.67 on Friday. The firm has a market capitalization of $37.96 billion, a P/E ratio of -709.85 and a beta of 0.58. The stock has a fifty day moving average of $642.61 and a 200-day moving average of $589.72. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.